CN101361893B - Traditional Chinese medicine combination for preventing and treating osteoporosis - Google Patents
Traditional Chinese medicine combination for preventing and treating osteoporosis Download PDFInfo
- Publication number
- CN101361893B CN101361893B CN2008101986686A CN200810198668A CN101361893B CN 101361893 B CN101361893 B CN 101361893B CN 2008101986686 A CN2008101986686 A CN 2008101986686A CN 200810198668 A CN200810198668 A CN 200810198668A CN 101361893 B CN101361893 B CN 101361893B
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- bone
- jizhuashen
- preventing
- rhizoma cibotii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine combination for preventing and curing rarefaction of bone, pertaining to the field of Chinese medicine. The combination takes Chinese medicinal materials as raw materials, is based on Chinese medical theory and modern research fruits, aims at the nosogenesis and the clinical symptom of the rarefaction of bone, and plays a role in increasing bone density, preventing fracture and stopping pains, thereby realizing the purposes of preventing and curing the rarefaction of bone. The traditional Chinese medicine combination can be prepared into various oral dosage forms for preventing and curing rarefaction of bone.
Description
Technical field
The present invention relates to a kind of osteoporotic Chinese medicine composition that prevents and treat, belong to the field of Chinese medicines.
Technical background
Osteoporosis is the common a kind of bone metabolism disease of old people, and there is trend in advance at the age at present, has become one of international public health problem.Its pathogenesis is also very not clear and definite always, be commonly considered as because of the variation of factors such as hormone regulating and controlling (estrogen, parathyroid hormone, calcitonin and activated vitamin D), nutritional status (calcium, phosphorus, protein and fat etc.), physical factor (motion, daylight), immunologic function and heredity closely related.Show the human endocrine Developmental and Metabolic Disorder, the bone amount of skeleton reduces, the bone fine structure destroys, and bone biomechanical property descends, with the disease of bones quality and quantity.Osteoporotic site of pathological change is human body axial bone and long bone of limbs backbone, and maximum harm is fracture, and common sympton is a pain, sees with lumbago and backache more, accounts for 70%-80%.A very long preclinical phase before taking place, osteoporotic fracture is arranged, the most outstanding during this time performance is exactly an osteodynia, comprise back and extremities joint ache, weak etc., pain spreads to both sides along spinal column, pain relief when dorsal position or seat is stretched after upright or the pain increased when standing for a long time, sitting, in the daytime pain relief, night and early morning increase the weight of when waking up, and bend over, muscular movement, cough, increase the weight of when stool exerts oneself.Present osteoporotic treatment is mainly based on calcium preparation, vitamin D3 class, estrogen, diphosphate etc.
The present invention is that the employing Chinese crude drug is a raw material, with theory of Chinese medical science and modern study result serves as according to the Chinese medicine composition that forms, at osteoporotic pathogenesis and clinical symptoms, play bone density improving, prevention fracture and analgesic effect, thereby reach prevention and treat osteoporotic purpose.
Chinese invention patent publication number CN1568965A discloses " a kind of medicine for the treatment of osteoporosis and preparation method thereof ", mainly make by Semen sojae atricolor total flavones, Herba Epimedii total flavones, this medicine reaches therapeutic effect by effect of estrogen sample and invigorating the kidney and strengthening the bones effect, but mineral effect in the not mentioned control agent.
Chinese invention patent publication number CN1618451A discloses " a kind of Chinese medicine composition for the treatment of osteoporosis and preparation method thereof ", and its effective ingredient mainly is to be that raw material is made by Cornu Cervi Pantotrichum, Herba Epimedii, Fructus Psoraleae, Herba Cistanches, Fructus Cnidii, Fructus Ligustri Lucidi.Have the kidney invigorating warming YANG, the effect of replenishing essence bone strengthening is applicable to that mainly Chinese medical discrimination belongs to the primary osteoporosis of insufficiency of kidney-YANG pattern of syndrome.Can significantly increase the animal blood calcium, the rising estrogen level; Suppress bone resorption, promote bone formation, make bone metabolism be in the positive balance state of bone formation, the bone amount is increased, thereby realize the osteoporotic purpose of control greater than bone resorption.But not mentioned have an analgesic effect.
Summary of the invention
The object of the invention provides a kind of osteoporotic Chinese medicine composition that prevents and treat, and under Chinese medical theory instructs, by the rational proportion of each medical material, forms the Chinese medicine composition with prevention and treatment osteoporosis effect.
Osteoporosis belongs to " atrophic debility of bones " category in motherland's medical science, according to according to " kidney governing bones ", menarche or exhaust and cause Human Physiology to change scheduling theory, this is generally admitted this disease in suffering from a deficiency of the kidney; In addition, weakness of the spleen and stomach, qi depression to blood stasis etc. also are considered to one of pathogenesis.So methods such as the kidney invigorating and essence nourishing, kidney-supplementing liver-boosting, kidney and spleen invigorating, invigorating kidney, promoting blood circulation QI invigorating are followed in treatment mostly.Modern medicine study shows that mineral such as calcium, magnesium, zinc, copper, manganese and multivitamin absorption have certain effect to prevention and treatment osteoporosis.
The most bone density of sufferers of osteoporosis face is low, the clinical manifestation of osteodynia.
The present invention is directed to osteoporotic pathogenesis and clinical symptoms, play bone density improving, prevention fracture and analgesic effect, thereby reach prevention and treat osteoporotic purpose.
Chinese medicine composition of the present invention is made up of three class medicines, and first kind medicine has Endoconcha Sepiae and Concha Ostreae, and it act as content of mineral substances in the control agent, bone density improving.Endoconcha Sepiae, salty, puckery, temperature is returned spleen, kidney channel, has astringing to arrest bleeding, relieving leukorrhea by astringents, skin ulcer is held back in antacid.Be used for Peptic Ulcers, hyperchlorhydria, hematemesis and epistaxis, metrorrhagia is had blood in stool, emission and spermatorrhea, leucorrhea with red and white discharge, stomachache acid regurgitation; The external treatment bleeding due to trauma, the many pus of skin ulcer.Concha Ostreae, salty, be slightly cold.Return liver, gallbladder, kidney channel, have tranquillization with heavy prescription, the YANG hyperactivity suppressing nourishing YIN, hard masses softening and resolving is restrained astringent or styptic treatment for spontaneous sweating effect.The second class medicine has Rhizoma Cibotii and Herba Sedi Leucocarpi, and it act as invigorating the liver and kidney, strong spinal column.Rhizoma Cibotii, bitter, sweet, temperature is returned liver, kidney channel.Has invigorating the liver and kidney, strong spinal column, the effect of wind-damp dispelling.It is aching and limp to be used for spinal column, weakness of the lower extremities, rheumatic arthralgia.Herba Sedi Leucocarpi, suffering, cold, return kidney; Liver Channel has heat-clearing and toxic substances removing, the effect of removing heat from blood.The 3rd class medicine has JIZHUASHEN and root of Rhapis excelsa (Thunb.) Henry-R. Flabelliformis Ait., and it act as analgesia.JIZHUASHEN, sweet, temperature has the spleen reinforcing stomach function regulating, and the effect of analgesia asthenia is used for the treatment of incoordination between the spleen and stomach, shortness of breath and fatigue, bones and muscles pain.Root of Rhapis excelsa (Thunb.) Henry-R. Flabelliformis Ait., sweet in the mouth is puckery; Property is put down, and has expelling wind and removing dampness, and the effect of astringing to arrest bleeding is used for the treatment of rheumatic arthralgia, epistaxis, spitting of blood, traumatic injury impairment caused by overstrain.All medicine mutual reinforcements between are usefulness, can control agent in content of mineral substances again can invigorating the liver and kidney, the effect of prevention and treatment osteoporosis is gathered in analgesia altogether.
The raw material sources of preparation medicine activity component of the present invention are in pressing the Chinese medicine that following weight portion is formed: Endoconcha Sepiae 10-30, Rhizoma Cibotii 5-15, JIZHUASHEN 5-15.
Preferred for preparation active component raw material weight of the present invention consists of: Endoconcha Sepiae 20, Rhizoma Cibotii 10, JIZHUASHEN 10.
The raw material sources of preparation medicine activity component of the present invention are in pressing the Chinese medicine that following weight portion is formed: Endoconcha Sepiae 10-30, Concha Ostreae 8-30, Rhizoma Cibotii 5-15, Herba Sedi Leucocarpi 10-30, root of Rhapis excelsa (Thunb.) Henry-R. Flabelliformis Ait. 10-25, JIZHUASHEN 5-15.
Preferred for preparation active component raw material components by weight percent of the present invention is: Endoconcha Sepiae 20, Concha Ostreae 12, Rhizoma Cibotii 10, Herba Sedi Leucocarpi 20, root of Rhapis excelsa (Thunb.) Henry-R. Flabelliformis Ait. 18, JIZHUASHEN 10.
Medicine of the present invention can be prepared into oral formulations with reference to the oral preparation method of various routines among " Chinese medicine preparation technology " (Yan Lixia chief editor).
The invention will be further elaborated below in conjunction with embodiment
Embodiment 1
Take by weighing medical material by following raw material weight component: Endoconcha Sepiae 10, Rhizoma Cibotii 5, JIZHUASHEN 5; Above-mentioned medical material decocts with water, and concentrates, and puts coldly, filter, and embedding, sterilization promptly gets oral liquid formulations of the present invention.
Embodiment 2
Take by weighing medical material by following raw material weight component: Endoconcha Sepiae 30, Rhizoma Cibotii 15, JIZHUASHEN 15; Above-mentioned medical material decocts with water, and concentrates, and puts coldly, filter, and embedding, sterilization promptly gets oral liquid formulations of the present invention.
Embodiment 3
Take by weighing medical material by following raw material weight component: Endoconcha Sepiae 10, Concha Ostreae 8, Rhizoma Cibotii 5, Herba Sedi Leucocarpi 10, root of Rhapis excelsa (Thunb.) Henry-R. Flabelliformis Ait. 10, JIZHUASHEN 5; Above-mentioned medical material decocts with water, and concentrates, and adds adjuvant, granulate, and drying, granulate promptly gets granular preparation of the present invention.
Embodiment 4
Take by weighing medical material by following raw material weight component: Endoconcha Sepiae 30, Concha Ostreae 30, Rhizoma Cibotii 15, Herba Sedi Leucocarpi 30, root of Rhapis excelsa (Thunb.) Henry-R. Flabelliformis Ait. 25, JIZHUASHEN 15; Above-mentioned medical material decocts with water, and concentrates, and adds adjuvant, granulate, and drying, granulate promptly gets granular preparation of the present invention.
Embodiment 5
Take by weighing medical material by following raw material weight component: Endoconcha Sepiae 20, Concha Ostreae 12, Rhizoma Cibotii 10, Herba Sedi Leucocarpi 20, root of Rhapis excelsa (Thunb.) Henry-R. Flabelliformis Ait. 18, JIZHUASHEN 10; Above-mentioned medical material decocts with water, and concentrates, and adds adjuvant, granulate, and drying, granulate incapsulates in the clothing, promptly gets capsule preparations of the present invention.
Experimental example 1
1 experimental technique
The SD male rat at 60 3 monthly ages is divided into 6 groups at random, i.e. matched group, model group, one group of intervention and intervene two groups, intervene three groups and intervene four groups.Every group 10.All the other five groups of rat skin lower injection first are sprinkled Buddhist nun 3.5mg/kg, subcutaneous injection, every day 1 time except that matched group.
Intervention group is irritated stomach simultaneously and is given medicine of the present invention:
Intervene one group (low dosage): Endoconcha Sepiae 10, Rhizoma Cibotii 5, JIZHUASHEN 5;
Intervene two groups (high doses): Endoconcha Sepiae 30, Rhizoma Cibotii 15, JIZHUASHEN 15;
Intervene three groups (low dosages): Endoconcha Sepiae 10, Concha Ostreae 8, Rhizoma Cibotii 5, Herba Sedi Leucocarpi 10, root of Rhapis excelsa (Thunb.) Henry-R. Flabelliformis Ait. 10, JIZHUASHEN 5.
Intervene four groups (high doses): Endoconcha Sepiae 30, Concha Ostreae 30, Rhizoma Cibotii 15, Herba Sedi Leucocarpi 30, root of Rhapis excelsa (Thunb.) Henry-R. Flabelliformis Ait. 25, JIZHUASHEN 15.
Above-mentioned two groups of used medical materials component by weight take by weighing, and decoct with water, and are converted into the mice consumption, gastric infusion, every day 1 time according to adult's dosage.Continuous 9 weeks.Measure bone density (BMD), serum osteocalcin (BGP) and serum calcium, phosphorus level after 9 weeks.
2 experimental results
Model group and matched group compare, and bone density all significantly reduces (P＜0.01), and intervention group and model group are relatively, and bone density all significantly increases (P＜0.01,0.05).Model group BGP obviously reduces than matched group BGP, P＜0.01.Intervention group and model group comparison BGP obviously increase (P＜0.01,0.05).Intervention group and model group compare, and serum calcium, phosphorus content all raise to some extent, and difference has the significance meaning, P＜0.01,0.05.Illustrate the present invention can control agent in content of mineral substances, bone density improving has certain prevention and therapeutical effect to osteoporosis.
The every desired value comparison of table 1 (X ± SD)
# and matched group compare, P＜0.01; * compare P＜0.05 with model group; * and model group compare, P＜0.01
Experimental example 2
1 experimental technique
50 Kunming mouses, female, body weight 18-22g is divided into 5 groups at random, promptly blank group, intervenes one group and intervene two groups, intervene three groups and intervene four groups.
Earlier water-bath is added suitable quantity of water, water temperature is controlled at (55 ± 0.5) ℃, gets the glass beaker of 1000ml, the interior water of its bottom surface and water-bath is fully contacted, be fixed preheating 10min, get one of mice at every turn and be put in the beaker, the pain threshold (s) that the sufficient time is designated as this Mus appears licking in mice.All pain thresholds less than 5s or greater than 50s or in beaker often the leaper all give it up.
Intervention group is irritated stomach simultaneously and is given medicine of the present invention:
Intervene one group (low dosage): Endoconcha Sepiae 10, Rhizoma Cibotii 5, JIZHUASHEN 5;
Intervene two groups (high doses): Endoconcha Sepiae 30, Rhizoma Cibotii 15, JIZHUASHEN 15;
Intervene three groups (low dosages): Endoconcha Sepiae 10, Concha Ostreae 8, Rhizoma Cibotii 5, Herba Sedi Leucocarpi 10, root of Rhapis excelsa (Thunb.) Henry-R. Flabelliformis Ait. 10, JIZHUASHEN 5.
Intervene four groups (high doses): Endoconcha Sepiae 30, Concha Ostreae 30, Rhizoma Cibotii 15, Herba Sedi Leucocarpi 30, root of Rhapis excelsa (Thunb.) Henry-R. Flabelliformis Ait. 25, JIZHUASHEN 15.
Above-mentioned two groups of used medical materials component by weight take by weighing, and decoct with water, and are converted into the mice consumption according to adult's dosage, gastric infusion, and blank group is irritated the normal saline that stomach gives same dose.Measure the normal pain threshold of every mice before the administration, 30min surveys the variation of its pain threshold again after the administration.Pain threshold is remembered with 60s greater than 60s.Measure the variation of administration front and back pain threshold, calculate pain threshold and the pain threshold raising rate of improving.
Pain threshold (s) after pain threshold (s)-administration before raising pain threshold (s)=administration
Threshold of pain raising rate (%)=(improving the preceding pain threshold of pain threshold/administration) * 100%
2 experimental results
Pain threshold does not have significant change before and after the administration of blank group, and pain threshold has obvious variation before and after the intervention group medication, and difference has significance, P＜0.01,0.05.Pain threshold obviously raises after the intervention group medication, illustrates that Chinese medicine composition of the present invention has certain analgesic activity.The results are shown in Table 2.
Pain threshold variation before and after table 2 administration (X ± SD)
* with before the medication compare P＜0.05; Compare P＜0.01 before * and the medication
Claims (5)
1. a prevention and treat osteoporotic Chinese medicine composition, the active component that it is characterized in that it mainly is that the raw material by following weight portion consists of: Endoconcha Sepiae 10-30, Rhizoma Cibotii 5-15, JIZHUASHEN 5-15.
2. according to the Chinese medicine composition of claim 1, its preparation active component raw material composition by weight is: Endoconcha Sepiae 20, Rhizoma Cibotii 10, JIZHUASHEN 10.
3. according to the Chinese medicine composition of claim 1, form other medical materials of increase on the basis at it, composition by weight is: Endoconcha Sepiae 10-30, Concha Ostreae 8-30, Rhizoma Cibotii 5-15, Herba Sedi Leucocarpi 10-30, root of Rhapis excelsa (Thunb.) Henry-R. Flabelliformis Ait. 10-25, JIZHUASHEN 5-15.
4. according to the Chinese medicine composition of claim 3, its preparation active component raw material composition by weight is: Endoconcha Sepiae 20, Concha Ostreae 12, Rhizoma Cibotii 10, Herba Sedi Leucocarpi 20, root of Rhapis excelsa (Thunb.) Henry-R. Flabelliformis Ait. 18, JIZHUASHEN 10.
5. according to any described Chinese medicine composition among the claim 1-4, it is characterized in that said composition can be prepared into conventional oral formulations.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101986686A CN101361893B (en) | 2008-09-16 | 2008-09-16 | Traditional Chinese medicine combination for preventing and treating osteoporosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101986686A CN101361893B (en) | 2008-09-16 | 2008-09-16 | Traditional Chinese medicine combination for preventing and treating osteoporosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101361893A CN101361893A (en) | 2009-02-11 |
| CN101361893B true CN101361893B (en) | 2010-11-03 |
Family
ID=40388621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008101986686A Expired - Fee Related CN101361893B (en) | 2008-09-16 | 2008-09-16 | Traditional Chinese medicine combination for preventing and treating osteoporosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101361893B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101757372B (en) * | 2009-10-20 | 2012-01-11 | 苏州派腾生物医药科技有限公司 | Composition for treating osteoporosis and preparation method thereof |
| CN103735947B (en) * | 2013-12-26 | 2016-02-10 | 赵鹏 | One treats osteoporotic Chinese medicine formula and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1065399A (en) * | 1992-05-15 | 1992-10-21 | 辽宁省中医研究院 | The preparation method of medicine tonifying kidney and bone |
| CN1096953A (en) * | 1993-07-02 | 1995-01-04 | 周勇 | A kind of Chinese medicine for the treatment of osteoporosis |
-
2008
- 2008-09-16 CN CN2008101986686A patent/CN101361893B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1065399A (en) * | 1992-05-15 | 1992-10-21 | 辽宁省中医研究院 | The preparation method of medicine tonifying kidney and bone |
| CN1096953A (en) * | 1993-07-02 | 1995-01-04 | 周勇 | A kind of Chinese medicine for the treatment of osteoporosis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101361893A (en) | 2009-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103893727B (en) | A kind of relieving pain and activating blood circulation relaxing muscles and tendons plaster and preparation method thereof | |
| CN1253201C (en) | Medicine for treating hemicrania | |
| CN103349753B (en) | Traditional Chinese medicine composition for treating kidney deficiency | |
| CN101361893B (en) | Traditional Chinese medicine combination for preventing and treating osteoporosis | |
| CN1211112C (en) | Gubenhuiyuan traditional Chinese medicine composition and its method for producing oral liquid | |
| CN102228584A (en) | Chinese medicinal preparation for treating helosis | |
| CN1201765C (en) | Chinese medicine ointment for treating arthrosis | |
| CN104623536A (en) | Chinese medicinal combination for treating insomnia | |
| CN101829163A (en) | Application of rhizoma nardostachyos in preparing medicine for preventing and treating osteoporosis | |
| CN1876171A (en) | Soup formulation medicine for treating kidney deficiency type chronic alvine flux and preparation method thereof | |
| CN105055636A (en) | Traditional Chinese medicine preparation for treating osteoporosis | |
| CN1911319A (en) | Decoction of herbal medicine for treating gynecologic amenorrhea, and its prepn. method | |
| CN109966355A (en) | One kind is removed obstruction in channels to relieve pain liquid medicine and preparation method thereof | |
| CN1224416C (en) | Chinese medicine for treating keloid | |
| CN110201097A (en) | A kind of Chinese medicine composition treating and preventing Hypertrophic osteopathy and preparation method | |
| CN109010549A (en) | Synthetism expelling wind and activating blood flow pain relieving ointment and preparation method thereof | |
| CN102641348B (en) | Collateral-dredging and pain-relieving powder and preparation method thereof | |
| CN106728973A (en) | A kind of Chinese medicinal capsule for treating cervical spondylopathy | |
| CN101530598A (en) | Plaster used for hyperosteogeny | |
| CN1242772C (en) | Chinese medicine for hemorrhoid | |
| CN1382466A (en) | Bone setting machine | |
| CN1772230A (en) | Medicine Yangrongtongbining | |
| CN104189744A (en) | Traditional Chinese medicine composition for treating elderly liver-qi-stasis type enuresis | |
| CN105250856A (en) | Chinese herb composition for treating climacteric syndrome | |
| CN104127709A (en) | Traditional Chinese medicinal composition for curing chronic renal insufficiency |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101103 Termination date: 20120916 |